Rami S. Komrokji, MD, clinical director, Hematologic Malignancies, Moffitt Cancer Center, discusses optimizing the management of treatment for myelodysplastic syndrome (MDS).
Because there are limited options approved for MDS, it is important that oncologists optimize treatment in order to achieve the best results, says Komrokji.
Biomarkers can be used to best select which treatment should be used first for MDS. It is also important to be familiar with the management, toxicities and response timelines for each treatment. This way, if a treatment is not working well, the physician can switch to a more optimal treatment regimen.
Komrokji says it is also important to determine the optimal time, if at all, to conduct a transplant. â€‹